What We’re Reading: Premature Death Risk Factors; Pfizer Vaccine Efficacy; CVD Symptom Disparities
August 24th 2022People who experienced childhood poverty and other adversities are at greater risk of premature death in adulthood; Pfizer’s COVID-19 vaccine is 73% effective in protecting children younger than 5 years; women experience more symptoms of heart failure and other cardiovascular diseases than men.
What We're Reading: OTC Hearing Aids; Respiratory Devices Failing; Postpartum Medicaid Extended
August 17th 2022A new FDA rule will allow hearing aids to be purchased without prescriptions; the FDA has received more than 48,000 reports of faulty Philips respiratory devices between May and July; HHS has extended postpartum Medicaid in Hawaii, Maryland, and Ohio.
Fakhri Reviews Considerations for Second-Line Therapy in DLBCL
August 16th 2022Nearly 5 years after approval of the first CAR T-cell therapy, treatment is moving into second line, and patients have more options than ever for diffuse large B-cell lymphoma. How do physicians choose? Bita Fakhri, MD, MPH, hematologist-oncologist at the University of California San Francisco, discusses the process.
What We're Reading: Drug Pricing Debate; Judge Rules Against Walgreens; Predicting TBI Outcomes
August 11th 2022Policy observers and industry stakeholders debate the possible spillover effects of Medicare drug pricing reform in the employer-based insurance market; a California federal judge rules Walgreens could be held liable for not investigating suspicious orders of opioids in San Francisco; a blood test performed the day of a traumatic brain injury (TBI) can predict which patients may die and who may survive with a disability.
What We’re Reading: Alzheimer Drug Setback; Rural Health Care Investment; Monkeypox Drug Delivery
August 10th 2022Acadia Pharmaceuticals’ pimavanserin (Nuplazid) was not extended by the FDA to include Alzheimer-related psychosis; HHS/Health Resources and Service Administration vow to strengthen rural health care; a new deal has the United States paying $26 million for Siga Technologies’ Tpoxx.